Organised by SHC
Singapore
MASLD Symposium
For the Clinician, Researcher and
Pharmaceutical Executive
Sunday, 24 August 2025
8:30 am to 5:00 pm (SGT)
Singapore MASLD Symposium
REGISTRATION FOR The 1st Asian Hepatology Summit includes Singapore MASLD Symposium 2025.
The Singapore MASLD Symposium 2025 will feature an extensive line up of World Renowned Experts from Academia AND Industry in the fast developing field of MASLD. They will share and provide a comprehensive update on their research works.
REGISTER HERE for 1st Asian Hepatology Summit which includes the Singapore MASLD Symposium at no extra charge
To access SHC e-Resources REGISTER HERE or LOG IN (if you have previously registered for SHC)
Meet Our Experts
coming Soon..
Singapore MASLD Symposium 2025 Scientific Programme
in Ballroom 2
Coming Soon..
August 2026
24
| Advancing Care in MASLD Programme | Time (SGT) |
|---|---|
| Welcome Address | 8.20 – 8.30 |
| Theme 1: Integration Chair: Dr. Mark Muthiah & Dr. Daniel Huang |
|
| Global format for care pathways in metabolic medicine – how is the world moving towards integration Prof. Arun Sanyal View Bio |
8.30 – 8.50 |
| A pathobiological view of common biological roots of metabolic end organ damage Prof. Quentin Antsee View Bio |
8.50 – 9.10 |
| Multi-organ outcomes in MASLD Prof. Dan Yock Young View Bio |
9.10 – 9.30 |
| Case based discussions: extrahepatic involvement in MASLD Dr. Nicholas Chew View Bio |
9.40 – 10.10 |
| Combined Q&A | 10.10 – 10.30 |
| Tea Break | 10.30 – 10.50 |
| Theme 2: Diagnostics Chair: Prof. Atsushi Nakajima and Prof. Ming Hua Zheng |
|
| Unmet needs in diagnostics: a patient centered view Prof. Chan Wah Kheong View Bio |
10.50 – 11.10 |
| From diagnostics to surrogate endpoints: current state of the art Prof. Quentin Anstee View Bio |
11.10 – 11.30 |
| Innovations in diagnostics Prof. Arun Sanyal View Bio |
11.30 – 11.50 |
| Case based discussions: challenges in diagnostics Prof. Atsushi Nakajima View Bio and Dr. Mark Muthiah View Bio |
11.50 – 12.20 |
| Combined Q&A | 12.20 – 12.40 |
| Gilead Sciences Lunch Symposium | 12.40 – 14.00 |
| a. Charting the path to HCV elimination in South East Asia – overview of national plans, screening targets, integration into primary care towards WHO 2030 goal Dr. John Ward View Bio |
12.45 – 13.05 |
| b. From diagnosis to cure: scale up test and treat and practical models to decentralise HCV care Prof. Philippa Easterbrook View Bio |
13.05 – 13.25 |
| c. Closing the gaps: Advancing Singapore towards HCV elimination Prof. Wong Chen Seong View Bio |
13.25 – 13.45 |
| d. Q&A | |
| Theme 3: Treatment Chair: Dr. Daniel Huang & Dr. Mark Muthiah |
|
| Top-down vs bottom up strategies in MASLD therapeutics? Prof. Arun Sanyal View Bio |
14.00 – 14.20 |
| Dual and triple agonists, are they better than single agonists of the incretin pathway? Prof. Elizabeth Powell View Bio |
14.20 – 14.40 |
| When and how of combination therapies Prof. Zheng Ming Hua View Bio |
14.40 – 15.00 |
| Case based discussion: management challenges Dr. Mark Muthiah View Bio Prof. Dan Yock Young View Bio |
15.00- 15.30 |
| Tea Break | 15.30 – 15.50 |
| Theme 4: Hot topics Chair: Dr. Yew Kuo Chao & Prof. Chan Wah Kheong |
|
| Non hepatic cancer in MASLD Prof. Asahiro Morishita View Bio |
15.50 – 16.10 |
| Implications of MASLD for women of childbearing years Dr. Mark Muthiah View Bio |
16.10 – 16.30 |
| Neurocognitive decline in MASLD Prof. Ajay Duseja View Bio |
16.30 – 16.50 |
| HCC and the core total in MASLD Dr. Daniel Huang View Bio |
16.50 – 17.10 |
| Combined Q&A | 17.10 – 17.30 |
| Closing address | 17.30 – 17.40 |
Who Should Attend?
Singapore MASLD Symposium 2025 is designed for Scientists (virologists, Immunologists), Clinician Scientists, pharmacists and Industry Experts, to exchange information on the latest research, discuss new developments in the management and treatment of MASLD
REGISTER HERE for 1st Asian Hepatology Summit which includes the Singapore MASLD Symposium at no extra charge
To access SHC e-Resources REGISTER HERE or LOG IN (if you have previously registered for SHC)